Europe
GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces its first half 2019 financial results.
Estimated total sales of HEMOBLAST™ Bellows for the first nine months of 2019 are expected to show strong growth at €2.5 million (compared to €1.5 million for the first half of 2019 and €0.6 million for the full year 2018) and are expected to be on track to achieve the 2019 revenue guidance range of €4.0-€4.5 million
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, announces interim results for the six months ended 30 June 2019.
TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo
Motif Bio plc announced unaudited financial results for the half year ended June 30, 2019 and reported on its progress year to date.
Creoptix AG announced that is has raised CHF 8 million in the first closing as part of a Series C financing round.
Insilico Biotechnology AG and the Janssen Pharmaceutical Companies of Johnson & Johnson announced an agreement to apply Insilico’s predictive Digital Twins for the early selection of high-performing cells to further boost efficiency and throughput of their cell line development workflow.
In the wake of the discovery that some Zantac products may contain a carcinogen contaminant due to the manufacturing process, three major drug store retailers in the United States have removed the antacid product from the shelves.
The U.S. Food and Drug Administration (FDA) rejected the company’s inhaled triple-combination therapy, PT010, now known as Breztri Aerosphere.
Janssen’s Invokana snagged another regulatory approval to reduce the risk of end-stage kidney disease, cardiovascular death and worsening of kidney function in adults with type 2 diabetes and diabetic kidney disease.
PRESS RELEASES